Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was well-tolerated with repeated, long-term dosing Plan to evaluate XTX202 as a monotherapy in ongoing Phase 2 proof-of-concept trial at 4.0 mg/kg in patients with advanced melanoma and renal cell carcinoma Xilio Therapeutics to host investor conference call and webcast on Monday, November 6, 2023 at 8:00 a.m.

剂量依赖性疾病控制率的初步证据，在一系列实体肿瘤类型中，较高剂量（≥2.8mg/kg）的疾病控制率为50%，所有剂量水平的疾病控制率为31%，包括冷肿瘤治疗相关不良事件主要是1-2级，剂量高达4 mg/kg，每三周在门诊就诊一次，没有报告血管渗漏综合征的体征或症状，两名患者继续治疗超过1年，证明XTX202耐受性良好，反复治疗，长期给药计划评估XTX202作为正在进行的2期概念验证试验中的单一疗法，在4.0 mg/kg的晚期黑色素瘤和肾细胞癌患者中进行Xilio Therapeutics，以主持投资者电话会议和网络广播，周一，11月62023年上午8:00。

ET WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced initial safety, pharmacokinetic (PK), pharmacodynamic (PD) and anti-tumor activity data from its ongoing Phase 1/2 clinical trial evaluating XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, in late line patients with advanced solid tumors.

ET WALTHAM，Mass。，2023年11月3日（GLOBE NEWSWIRE）-Xilio Therapeutics，Inc。（纳斯达克股票代码：XLO），一家临床阶段生物技术公司，为癌症患者发现和开发肿瘤激活的免疫肿瘤疗法，今天宣布了正在进行的评估XTX202的1/2期临床试验的初始安全性，药代动力学（PK），药效学（PD）和抗肿瘤活性数据，晚期实体瘤患者的研究性肿瘤激活，工程化，β-γIL-2。

The data were presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA being held on November 1-5, 2023. “The newly reported data from our Phase 1/2 clinical trial for XTX202 expands the evidence across our programs supporting clinical validation of our tumor-activated technology.

数据于2023年11月1日至5日在加利福尼亚州圣地亚哥举行的癌症免疫治疗学会（SITC）第38届年会上公布。“我们针对XTX202的1/2期临床试验的新报告数据扩展了我们计划中的证据，支持我们的肿瘤激活技术的临床验证。

We observed a disease control rate of 50% at higher doses (≥2.8 mg/kg) and 31% across all dose levels in a variety of advanced and IO refractory solid tumors.

在各种晚期和IO难治性实体瘤中，我们观察到较高剂量（≥2.8mg/kg）的疾病控制率为50%，所有剂量水平的疾病控制率为31%。